SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-100179
Filing Date
2023-09-13
Accepted
2023-09-12 21:51:06
Documents
14
Period of Report
2023-09-11
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2324916d1_8k.htm   iXBRL 8-K 46095
2 EXHIBIT 99.1 tm2325960d1_ex99-1.htm EX-99.1 51245
3 EXHIBIT 99.2 tm2325960d1_ex99-2.htm EX-99.2 86201
  Complete submission text file 0001104659-23-100179.txt   393024

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA srne-20230911.xsd EX-101.SCH 3051
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE srne-20230911_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE srne-20230911_pre.xml EX-101.PRE 22383
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2324916d1_8k_htm.xml XML 3117
Mailing Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121
Business Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121 858-203-4100
Sorrento Therapeutics, Inc. (Filer) CIK: 0000850261 (see all company filings)

IRS No.: 330344842 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36150 | Film No.: 231251523
SIC: 2836 Biological Products, (No Diagnostic Substances)